Taro Pharmaceutical Industries Ltd. (TARO): Price and Financial Metrics

Taro Pharmaceutical Industries Ltd. (TARO): $42.04

0.09 (-0.21%)

POWR Rating

Component Grades








Add TARO to Watchlist
Sign Up

TARO Price/Volume Stats

Current price $42.04 52-week high $45.76
Prev. close $42.13 52-week low $23.92
Day low $42.00 Volume 26,300
Day high $42.19 Avg. volume 49,786
50-day MA $42.18 Dividend yield N/A
200-day MA $38.96 Market Cap 1.58B

TARO Stock Price Chart Interactive Chart >

Taro Pharmaceutical Industries Ltd. (TARO) Company Bio

Taro Pharmaceutical Industries offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1959 and is based in Haifa Bay, Israel.

TARO Latest News Stream

Event/Time News Detail
Loading, please wait...

TARO Latest Social Stream

Loading social stream, please wait...

View Full TARO Social Stream

Latest TARO News From Around the Web

Below are the latest news stories about TARO PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TARO as an investment opportunity.

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Yahoo | December 28, 2023

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

Yahoo | December 26, 2023

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Yahoo | December 26, 2023

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.

Yahoo | December 22, 2023

Taro Provides Results for September 30, 2023


Yahoo | October 26, 2023

Read More 'TARO' Stories Here

TARO Price Returns

1-mo -0.24%
3-mo N/A
6-mo 20.35%
1-year 71.03%
3-year -43.53%
5-year -60.06%
YTD 0.62%
2023 43.87%
2022 -42.05%
2021 -31.75%
2020 -16.50%
2019 3.89%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!